| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4520107
Max Phase: Preclinical
Molecular Formula: C19H19N3O2S
Molecular Weight: 353.45
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: CC1=NC(c2cn(S(=O)(=O)c3ccccc3)c3ccc(C)cc23)CN1
Standard InChI: InChI=1S/C19H19N3O2S/c1-13-8-9-19-16(10-13)17(18-11-20-14(2)21-18)12-22(19)25(23,24)15-6-4-3-5-7-15/h3-10,12,18H,11H2,1-2H3,(H,20,21)
Standard InChI Key: NROCYIRJNRNAGU-UHFFFAOYSA-N
Associated Targets(Human)
Kallikrein 7 657 Activities
Associated Targets(non-human)
Kallikrein-7 46 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 353.45 | Molecular Weight (Monoisotopic): 353.1198 | AlogP: 3.25 | #Rotatable Bonds: 3 |
| Polar Surface Area: 63.46 | Molecular Species: BASE | HBA: 5 | HBD: 1 |
| #RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: 9.74 | CX LogP: 2.70 | CX LogD: 0.62 |
| Aromatic Rings: 3 | Heavy Atoms: 25 | QED Weighted: 0.79 | Np Likeness Score: -0.73 |
References
| 1. Murafuji H, Muto T, Goto M, Imajo S, Sugawara H, Oyama Y, Minamitsuji Y, Miyazaki S, Murai K, Fujioka H.. (2019) Discovery and structure-activity relationship of imidazolinylindole derivatives as kallikrein 7 inhibitors., 29 (2): [PMID:30522951] [10.1016/j.bmcl.2018.11.011] |
Source
Source(1):